HIV
Study links monocyte “biological aging” in blood to emotional depression symptoms in women with and without HIV
Riportato dall'IA Immagine generata dall'IA Verificato
A study of 440 participants from the Women’s Interagency HIV Study found that accelerated epigenetic aging in monocytes—an immune cell type—tracked more closely with emotional and cognitive depression symptoms such as hopelessness and loss of pleasure than with physical symptoms like fatigue. The work, published in The Journals of Gerontology: Series A, adds evidence that cell-type-specific aging measures could contribute to future biological tools to complement symptom-based depression screening, though researchers say more validation is needed before clinical use.
Uno studio pubblicato lunedì su Nature Microbiology conferma la remissione a lungo termine dall'HIV nel «paziente di Oslo», un uomo di 62 anni trattato per mielodisplasia tramite un trapianto di cellule staminali ricevuto dal fratello, portatore della mutazione CCR5 Delta 32. Il paziente non assume antiretrovirali da quattro anni e il virus non è rilevabile. Si tratta del decimo paziente considerato guarito in questo modo.
Riportato dall'IA
Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency have approved lenacapavir as pre-exposure prophylaxis (PrEP) for uninfected individuals at high risk. This antiretroviral drug is administered via subcutaneous injections every six months, providing an alternative to daily pills. The World Health Organization endorses its use in comprehensive prevention strategies.
Riportato dall'IA
A Cuba, 35.373 persone vivono con il virus dell’immunodeficienza umana (HIV), una cifra stabile grazie al programma nazionale efficace. Le nuove diagnosi sono calate del 14,5%, e i decessi correlati del 39%. Questi risultati evidenziano l’impegno dello Stato cubano per l’accesso universale alla salute.